JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 77 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $243,000 | -35.0% | 35,700 | -1.9% | 0.00% | -25.0% |
| Q1 2021 | $374,000 | +175.0% | 36,400 | +87.6% | 0.00% | +100.0% |
| Q4 2020 | $136,000 | -14.5% | 19,400 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $159,000 | -77.2% | 19,400 | -80.8% | 0.00% | -80.0% |
| Q2 2020 | $697,000 | +45.2% | 100,900 | 0.0% | 0.01% | +25.0% |
| Q1 2020 | $480,000 | -45.3% | 100,900 | 0.0% | 0.01% | -11.1% |
| Q4 2019 | $878,000 | +157.5% | 100,900 | -1.5% | 0.01% | +125.0% |
| Q3 2019 | $341,000 | -32.7% | 102,400 | 0.0% | 0.00% | -20.0% |
| Q2 2019 | $507,000 | -22.0% | 102,400 | -2.2% | 0.01% | -28.6% |
| Q1 2019 | $650,000 | +12900.0% | 104,700 | +7378.6% | 0.01% | – |
| Q4 2018 | $5,000 | – | 1,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |